Bill Purdy’s Post

Follow for more pharma industry updates!

The 2024 CNS Summit Digital Innovation Index highlights the top companies advancing pharmaceutical innovation, developed in partnership with IDEA Pharma | From R&D to RxD. This annual assessment recognizes excellence in Clinical Development, Commercial Partnerships, and Digital Therapeutics. In 2024, Roche took the #1 spot, highlighting their achievements in remote patient monitoring and AI-driven innovations. See the top 10 innovators of 2024 below and download the full Index here: https://lnkd.in/ehrWJScV #CNSSummit #PharmaInnovation #AIinHealthcare #CNS2024 #HealthcareTech

Read this article about living with migraine, where my colleague and I share stories about our personal experience with migraine. The article also contains data from our Research Partnership syndicated studies in migraine. https://lnkd.in/eXa9wdAu

With the European Headache Congress in Rotterdam this month, we spoke to Research Partnership employees, including Tilly Lowkis, Associate Director, who shed light on how it feels to be a migraine sufferer. Using recent data from RP’s syndicated research conducted amongst HCPs and patients, we ask whether new pharmaceutical treatment options offer hope for this debilitating, yet unseen condition. Learn more in our recent blog here: https://lnkd.in/ehgksd3f #MigraineRelief #TherapyWatch #LivingWithMigraine #MarketResearch #PatientSupport

The CNIC is pleased to welcome CUP Contract Labs as our newest international member organization. We look forward to working with them as they increase their collaboration with global partners and work to address supply chain gaps across the international radiopharmaceutical sector. Read more about our partnership on our website here: https://lnkd.in/gd4rQZ-w

Citeline Senior Analyst David S. Dahan shares what GSK must do before its antibody-drug conjugate Blenrep can reach blockbuster status: https://ow.ly/Tv1R50UoIxY in this PharmaVoice article. _____ Follow Citeline the leading provider of drug, device, company, clinical trial and market intelligence in the pharmaceutical and medtech markets. #ADC #CancerResearch #MultipleMyeloma #ImmunoOncology #BloodCancer

Discover how Ingenious e-Brain’s strategic insights enabled a pharmaceutical company to effectively position Drug X for optimal pricing and acceptance in the competitive oncology market. Our evidence-based approach guided the client through complex pricing strategies, ensuring the successful navigation of payer expectations.   Read the detailed case study to explore further: https://lnkd.in/dfFmCE_U #pharmastrategy #oncologymarket #drugpricing #payerstrategy #pharmaceuticals #marketaccess #evidencebased #healthcareconsulting #pricingstrategy #pharmacasestudy #futureproofingbusinesses

🌟 De Novo FDA Approvals in October 2024! 🌟 In October, the FDA approved four ground breaking #NewDrugs, marking important progress in the #Pharmaceutical industry. These #BreakthroughTherapies bring renewed hope and expanded treatment options for patients worldwide. It’s inspiring to see such advancements shaping the future of healthcare! Iterum Therapeutics plc Astellas Pharma Pfizer Genentech #USFDA #FDAApprovals #Pharmaceuticals #PharmaInnovation #BreakthroughTherapies #PatientCare #Orlynvah #Vyloy #Hympavzi #Itovebi #uUTI #Adenocarcinoma #Hemophilia #BreastCancer #RASLSSConsulting #MarketIntelligence #MarketResearch #MarketEntryStrategy #CompetitiveIntelligence #StrategySupport #PortfolioOptimization Know more about #RASLSSConsulting: https://lnkd.in/d_daJ5Xv Follow our page for more industry updates: https://lnkd.in/de5zNWmK

Last week, I had the privilege to participate in a panel discussion alongside Middle Eastern regulators, where we explored the challenges and opportunities of conducting early-phase clinical trials in the region and their impact on patient centricity and access to innovative treatments. During the Q&A session, attendees discussed enhancing the clinical trial ecosystem in the region where we provided insights from the pharmaceutical industry. #Abbvie #clinicaltrials #diamiddleeast2024 #clinicaltrialecosystem

📢 Asieris Pharmaceuticals is thrilled to share our 2023 Annual Report, highlighting a year of remarkable achievements! Our flagship drug, APL-1702, has not only succeeded in global Phase III clinical trials but also set new benchmarks in treatment efficacy. Additionally, our innovative APL-1706 has officially received NDA acceptance. A special shoutout to our Specialty Commercial Team, whose efforts have significantly bolstered our revenue streams. Dive into more on our website and follow us for more exciting updates! #AsierisPharmaceuticals #AnnualReport #ClinicalTrials #Innovation